Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Anheuser-Busch Inbev SA — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Anheuser-Busch Inbev SA trades at $79.97 (market cap $163.79B). The key difference: Anheuser-Busch Inbev SA is far larger — about 17.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Anheuser-Busch Inbev SA pays a 1.62% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | BUD | |
|---|---|---|
Market Cap | $9.39B | $163.79B |
Sector | Health | Consumer Staples |
52-Week High | $356.25 | $86.48 |
52-Week Low | $241.71 | $57.93 |
Enterprise Value | $9.14B | $228.20B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
BUD trades at $83.76, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $90.17. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 expected, while revenue trends show modest growth, and net income margin improved to 11.52% in 2025. Cash flow remains positive, and debt-to-asset ratios have declined steadily since 2021.
The outlook is positive given strong analyst buy ratings (57.78%) and projected earnings growth, but risks include competitive pressures and macroeconomic sensitivity. The stock offers value with a P/E of 18.05 and stable profitability, though investor sentiment is mixed amid recent institutional selling and news of a major shareholder divestment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
